CYP2E1
| edit |
| Cytochrome P450, family 2, subfamily E, polypeptide 1
| ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | CYP2E1; CPE1; CYP2E; P450-J; P450C2E | |||||||||||||
| External IDs | OMIM: 124040 MGI: 88607 Homologene: 68089 | |||||||||||||
| ||||||||||||||
| RNA expression pattern | ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 1571 | 13106 | ||||||||||||
| Ensembl | ENSG00000130649 | ENSMUSG00000025479 | ||||||||||||
| Uniprot | P05181 | Q05421 | ||||||||||||
| Refseq | NM_000773 (mRNA) NP_000764 (protein) |
NM_021282 (mRNA) NP_067257 (protein) | ||||||||||||
| Location | Chr 10: 135.19 - 135.22 Mb | Chr 7: 140.62 - 140.63 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
|
WikiDoc Resources for CYP2E1 | |
|
Articles | |
|---|---|
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on CYP2E1 at Clinical Trials.gov Clinical Trials on CYP2E1 at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on CYP2E1
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating CYP2E1 Risk calculators and risk factors for CYP2E1
| |
|
Healthcare Provider Resources | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Cytochrome P450 2E1 (abbreviated CYP2E1, EC 1.14.14.1), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. While it is involved only in the oxidative metabolism of a small range of substrates (mostly small polar molecules), there are many important drug interactions mediated by CYP2E1.
CYP2E1 Ligands
| Substrates | Inhibitors | Inducers |
|---|---|---|
| Often mentioned: [2]
Other:
|
Strong: [3]
unspecified: |
|
Regulation of CYP2E1
Within one day of birth, the rat hepatic CYP2E1 gene is activated transcriptionally. CYP2E1 expression is easily inducible. It seems that there exist two stages of induction, a posttranslational mechanism for increased protein stability at low levels of ethanol, and an additional transcriptional induction at high levels of ethanol[4]
See also
References
- ↑ Where classes of agents are listed, there may be exceptions within the class
- ↑ Mentioned both in the reference named FASS and were previously mentioned in Wikipedia. Further contributions may follow other systems
- ↑ Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta för förskrivare)
- ↑ Charles S. Lieber. 1999. Microsomal Ethanol-Oxidizing System (MEOS) The First 30 Years (1968-1998)-A Review. Alcoholism: Clinical and Experimental Research 23(6):991-1007
Further reading
- Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica 28 (12): 1129–65. PMID 9890157.
- Kessova I, Cederbaum AI (2003). "CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury". Curr. Mol. Med. 3 (6): 509–18. doi:10.2174/1566524033479609. PMID 14527082.
Oxidoreductases: dioxygenases, including steroid hydroxylases (EC 1.14) | |
|---|---|
| 1.14.11 - 2-oxoglutarate | Prolyl hydroxylase - Lysyl hydroxylase |
| 1.14.13 - NADH or NADPH | Flavin-containing monooxygenase - Nitric oxide synthase - Cholesterol 7 alpha-hydroxylase - Methane monooxygenase - 3A4 -51A1 |
| 1.14.14 - reduced flavin or flavoprotein | 19A1 - 2D6 - 2E1 |
| 1.14.15 - reduced iron-sulfur protein | 11B1 - 11B2 - 11A1 |
| 1.14.16 - reduced pteridine | Phenylalanine hydroxylase - Tyrosine hydroxylase - Tryptophan hydroxylase |
| 1.14.17 - reduced ascorbate | Dopamine beta hydroxylase |
| 1.14.18-19 - other | Tyrosinase - Stearoyl-CoA desaturase-1 |
| 1.14.99 - miscellaneous | Cyclooxygenase - Heme oxygenase (HMOX1) - Squalene monooxygenase - 17A1 - 21A2 |
Cytochromes, oxygenases: cytochrome P450 (EC 1.14) | |
|---|---|
| CYP1 | A1, A2, B1 |
| CYP2 | A6, A7, A13, B6, C8, C9, C18, C19, D6, E1, F1, J2, R1, S1, U1, W1 |
| CYP3 | A4, A5, A7, A43 |
| CYP4 | A11, A22, B1, F2, F3, F8, F11, F12, F22, V2, X1, Z1 |
| CYP5-20 | CYP5 (A1) - CYP7 (A1, B1) - CYP8 (A1, B1) - CYP11 (A1, B1, B2) - CYP17 (A1) - CYP19 (A1) - CYP20 (A1) |
| CYP21-51 | CYP21 (A2) - CYP24 (A1) - CYP26 (A1, B1, C1) - CYP27 (A1, B1, C1) - CYP39 (A1) - CYP46 (A1) - CYP51 (A1) |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies


